UnitedHealth Group reported Q3 adjusted earnings of $4.69 per share, beating estimates by 13.9% with a 60.6% year-over-year increase. The company raised its 2026 EPS outlook to at least $20.50, driven by improved margins and lower medical costs. However, membership declined to 48.3 million from 50.1 million, raising questions about long-term sustainability. Optum also showed strong recovery with margins expanding to 5.6%. The stock carries a Zacks Rank #2 (Buy) rating with valuation below historical medians.

BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio.

With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment.

UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings.

Centene Corporation will launch its National Performance-Based Gold Card Program nationwide in November 2026, covering over 160,000 providers and allowing qualifying providers to bypass prior authorization for eligible outpatient services. The initiative aims to reduce administrative burden and processing costs while maintaining clinical oversight. Centene trades at 13.13x forward earnings with 2026 EPS estimated to grow 135.1% to $4.89, though the stock carries a Zacks Rank #4 (Sell) rating.

UnitedHealth Group raised its 2026 adjusted EPS guidance to at least $20.50 and signaled a return to sustainable earnings growth in 2027. The company reported strong Q3 results with adjusted earnings of $4.69 per share exceeding expectations. While commercial medical costs remain elevated and Medicaid funding gaps persist, Optum Health's earnings rebound and AI expansion initiatives support the recovery outlook.

UnitedHealth Group (UNH) has been identified as a top-ranked momentum stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company received upward earnings estimate revisions, with the consensus estimate increasing to $19.85 per share for fiscal 2026, and has demonstrated a strong average earnings surprise of +14%. The stock is recommended for momentum investors seeking exposure to the healthcare sector.

UnitedHealth and Johnson & Johnson both raised full-year guidance after Q3 earnings, but with contrasting performance. UnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management, while J&J saw earnings decline 7.5% YoY despite pharmaceutical growth offsetting weak MedTech performance. UnitedHealth is recommended as the better buy due to stronger earnings momentum, lower valuation (19X vs 23X forward earnings), and higher dividend yield (2.45% vs 2%).

Oscar Health raised its 2026 operating earnings guidance to $500M-$700M from $250M-$450M, driven by improved medical loss ratios (75% from 83%), disciplined pricing, and technology-driven expense efficiency. However, the company faces headwinds in the second half including 2%-4% monthly churn, rising medical costs, and open-enrollment spending. Revenue guidance remained unchanged at $18.7B-$19B.

Oscar Health (OSCR) demonstrates impressive growth with Q2 revenues surging 70.4% to $4.9 billion and membership jumping 46.2% to 2.96 million, significantly outpacing a contracting ACA market. However, the stock trades at a premium valuation of 5.5X tangible book value versus the sub-industry's 1.2X, leaving limited room for disappointment. Execution risks include rising churn rates, increasing medical costs, and favorable reserve items that may not repeat, though the company maintains a strong capital base of $10.2 billion.

Oscar Health (OSCR) shares have gained 14.9% over three months, driven by 46.2% year-over-year membership growth to 2.96 million members and improved medical economics. The company's medical loss ratio improved to 75% from 83%, while SG&A expenses fell to 14.7% from 17.2%, supported by technology efficiencies. However, the stock faces headwinds from ACA market contraction and a valuation that already reflects higher expectations.

Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations.